PARP battle heats up as Pfizer nabs priority review for talazoparib in breast cancer

PARP battle heats up as Pfizer nabs priority review for talazoparib in breast cancer

Last year at this time, Pfizer’s $14 billion purchase of Medivation was being cited as a cautionary tale of M&A gone wrong, after one product of that deal—prostate cancer drug Xtandi—turned in disappointing data at the annual confab of the American Society of Clinical Oncology (ASCO). Pfizer also paid top dollar for Medivation for its[…]

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual meeting, it rolled out data to support that notion. Click here to view original web page at www.fiercepharma.com

A 2-pronged attack could improve targeted therapies for colon cancer

A 2-pronged attack could improve targeted therapies for colon cancer

Two pathways have long been of interest to researchers studying colon cancer: Notch and MAPK. But drugs designed to target either pathway have proven disappointing. Now a team of researchers in Germany has made a discovery that sheds light on those disappointments—and provides insight that could improve colon cancer treatment. Click here to view original[…]

Merck's Keytruda, Roche's Tecentriq may lag chemo in some cancer patients, FDA says

Merck’s Keytruda, Roche’s Tecentriq may lag chemo in some cancer patients, FDA says

Roche’s Tecentriq and Merck’s Keytruda have been associated with decreased survival in some patients with low levels of PD-L1, the biomarker those two drugs are designed to target. (Roche) Merck and Roche’s immunotherapies are each approved solo for certain previously untreated bladder cancer patients. Click here to view original web page at www.fiercepharma.com